Aktieanalyser från populära analyshus

Senaste aktieanalyserna

Suominen: Start of a new journey - Nordea

Analys | Nordea

•

30 Oct 2025 07:18

Suominen: Start of a new journey - Nordea

Suominen

Analys | Analysguiden

•

29 Oct 2025 15:20

Prisma Properties: Kraftfull acceleration i tredje kvartalet - Analysguiden

Fastighetsbolaget Prisma Properties fortsätter att överträffa förväntningarna med en imponerande res...

Raysearch (Q3 preview): Expectations of record sales in Q3 - Redeye

RaySearch Laboratories

Analys | Evli

•

29 Oct 2025 13:23

Etteplan: Profitability resilient despite weak demand - Evli

Etteplan issued a profit warning yesterday alongside preliminary Q3 figures.

Devyser (Q3 preview): Quarterly fluctuations suggest uncertain estimates - Redeye

Suominen: Volume recovery further delayed - Evli

Suominen’s Q3 results were known beforehand since the company released preliminary information about...

Solteq: Weaker than expected quarter - Evli

Dovre Group: Losses were already known - Evli

Dovre issued another negative profit warning earlier this month and then disclosed Q3 EBIT to be abo...

Suominen: Strong cash flows in Q3 - Nordea

Senzime (Q3 Initial take): Slightly softer sales than expected, but EBIT in line - Redeye

Redeye provides an initial take following Senzime’s Q3 2025 report.

Senzime

Analys | Analysguiden

•

29 Oct 2025 09:47

Hanza: Riskprofil har varit bättre - Analysguiden

Hanza

Analys | ABG Sundal Collier

•

29 Oct 2025 09:34

Svedbergs Group Q3: 12% EBITA growth, all segments contribute - ABG

* Net sales SEK 529m, +2% vs ABGSCe, +3% vs Factset cons.

Arise (Q3 Preview): Updated production estimates - Redeye

Aspo: Several transactions have reshaped the company - Nordea

Aspo sold its Leipurin segment at a relatively good price in Q3 2025.

Taaleri: Fair value shifts led Q3 outcomes - Nordea

Truecaller (Q3 Review): Soft quarter, strong foundation - Redeye

Redeye provides an update following Truecaller’s Q3 2025 report, which came in below expectations du...

Truecaller

Analys | ABG Sundal Collier

•

29 Oct 2025 07:16

Nolato: No drama, just solid delivery - ABG

Nolato

Analys | Analysguiden

•

29 Oct 2025 07:15

VAXXA: Fortsatt marginalpress men stärkt kassa - Analysguiden

Vaxxa redovisade totala intäkter på 24,6 MSEK under Q3 2025, en ökning med 14 % mot föregående år.

Vaxxa

Analys | ABG Sundal Collier

•

28 Oct 2025 15:44

Nolato: Slight beat on adj. EBITA - ABG

Marimekko: Expecting strong development - Evli

Marimekko is set to report Q3 figures on Friday, October 31.

Oriola: Growth in place, profitability next - Evli

Truecaller (Q3 Initial take): Softer than expected - Redeye

Redeye comments on Truecaller’s Q3 2025 report, which came in softer than expected.

Annexin (Q3’25 Review): Clinical study in focus - Redeye

Taaleri: Fair value changes as the main driver in Q3 - Nordea

Taaleri’s Q3 2025 continuing earnings of EUR 10.1m increased by 4% y/y and came 5% above our estimat...

Nitro Games (Q3 Review): Balancing a soft market with new business optionality - Redeye

Heliospectra (Q3 Review): Building the foundation for growth in 2026 and beyond - Redeye

Redeye has revised its estimates following Heliospectra’s Q3 2025 report.

Heliospectra

Analys | Analysguiden

•

27 Oct 2025 16:39

Fastpartner: Ett lägre räntenetto lyfter förvaltningsresultatet - Analysguiden

Fastpartner

Analys | Analysguiden

•

27 Oct 2025 15:11

Beijer Alma: Stark organisk tillväxt och förbättrade marginaler - Analysguiden

Beijer Alma levererar en mycket stark rapport för det tredje kvartalet som visar på både en hög orga...

Beijer Alma

Analys | Analysguiden

•

27 Oct 2025 15:10

Eastnine: Ett nytt förvärv verkar komma allt närmare - Analysguiden

Polygiene Group (Q3 Review): Recovery in Sight - Redeye

Redeye returns with a more optimistic outlook following Polygiene’s Q3 2025 report, which presented ...

Polygiene

Föregående Nästa